المؤلفون: van den Boogaard, ML, Oka, R, Hakkert, A, Schild, L, Ebus, ME, van Gerven, MR, Zwijnenburg, DA, Molenaar, P, Hoyng, LL, Dolman, MEM, Essing, AHW, Koopmans, B, Helleday, T, Drost, J, van Boxtel, R, Versteeg, R, Koster, J, Molenaar, JJ

المصدر: Proceedings of the National Academy of Sciences of the United States of America. 118(36)

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:147833069

المؤلفون: Eleveld TF; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Oncogenomics, Amsterdam UMC, Amsterdam, Netherlands., Vernooij L; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Schild L; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Koopmans B; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Alles LK; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Ebus ME; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Dandis R; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van Tinteren H; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Caron HN; Hoffmann-La Roche, Basel, Switzerland., Koster J; Department of Oncogenomics, Amsterdam UMC, Amsterdam, Netherlands., van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Tytgat GAM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Eising S; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Versteeg R; Department of Oncogenomics, Amsterdam UMC, Amsterdam, Netherlands., Dolman MEM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, NSW, Australia., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pharmaceutical sciences, Utrecht University, Utrecht, Netherlands.

المصدر: Frontiers in oncology [Front Oncol] 2023 Feb 21; Vol. 13, pp. 1130034. Date of Electronic Publication: 2023 Feb 21 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Clement SC; Department of Pediatrics, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands., Koster J; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Kuiper RP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Human Genetics, Radboud University Medical Center, Nijmegen Center for Molecular Life Sciences, Nijmegen, the Netherlands., Tytgat GAM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Ebus ME; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Schild L; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Gilissen C; Department of Human Genetics, Radboud University Medical Center, Nijmegen Center for Molecular Life Sciences, Nijmegen, the Netherlands., Zwijnenburg DA; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Versteeg R; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands., van Santen HM; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.

المصدر: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2022 Jul; Vol. 34 (7), pp. e318-e319. Date of Electronic Publication: 2022 Apr 07.

نوع المنشور: Letter; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE

مواضيع طبية MeSH: Neuroblastoma*/genetics , Thyroid Neoplasms*/genetics , Thyroid Neoplasms*/pathology, Child ; Genomics ; Humans

المؤلفون: Poon E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Liang T; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA., Jamin Y; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Walz S; Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany., Kwok C; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Hakkert A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Barker K; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Urban Z; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Thway K; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom., Zeid R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hallsworth A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Box G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Ebus ME; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Licciardello MP; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Sbirkov Y; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Lazaro G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Calton E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Costa BM; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Valenti M; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., De Haven Brandon A; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Webber H; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Tardif N; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Almeida GS; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Christova R; Division of Clinical Studies and., Boysen G; Division of Clinical Studies and., Richards MW; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Barone G; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Ford A; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom., Bayliss R; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Clarke PA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., De Bono J; Division of Clinical Studies and., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Blagg J; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Robinson SP; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Eccles SA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Zheleva D; Cyclacel Ltd., Dundee, United Kingdom., Bradner JE; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Molenaar J; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Vivanco I; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Eilers M; Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany., Workman P; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Lin CY; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA., Chesler L; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.

المصدر: The Journal of clinical investigation [J Clin Invest] 2020 Nov 02; Vol. 130 (11), pp. 5875-5892.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: Adenosine/*analogs & derivatives , Cyclin-Dependent Kinase 2/*antagonists & inhibitors , Cyclin-Dependent Kinase 9/*antagonists & inhibitors , N-Myc Proto-Oncogene Protein/*biosynthesis , Neuroblastoma/*drug therapy , Temozolomide/*pharmacology, Adenosine/pharmacology ; Cell Line, Tumor ; Cyclin-Dependent Kinase 2/metabolism ; Cyclin-Dependent Kinase 9/metabolism ; Enhancer Elements, Genetic ; Humans ; N-Myc Proto-Oncogene Protein/genetics ; Neuroblastoma/genetics ; Neuroblastoma/metabolism ; Neuroblastoma/pathology ; Positive Transcriptional Elongation Factor B/genetics ; Positive Transcriptional Elongation Factor B/metabolism ; Transcription, Genetic/drug effects

المؤلفون: Eleveld TF; Department of Translational Research, Princess Maxima Centre for Childhood Oncology, Utrecht, the Netherlands. t.f.eleveld@prinsesmaximacentrum.nl.; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Schild L; Department of Translational Research, Princess Maxima Centre for Childhood Oncology, Utrecht, the Netherlands., Koster J; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Zwijnenburg DA; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Alles LK; Department of Translational Research, Princess Maxima Centre for Childhood Oncology, Utrecht, the Netherlands., Ebus ME; Department of Translational Research, Princess Maxima Centre for Childhood Oncology, Utrecht, the Netherlands., Volckmann R; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Tijtgat GA; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., van Sluis P; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Versteeg R; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Molenaar JJ; Department of Translational Research, Princess Maxima Centre for Childhood Oncology, Utrecht, the Netherlands.

المصدر: Cancer research [Cancer Res] 2018 Nov 01; Vol. 78 (21), pp. 6297-6307. Date of Electronic Publication: 2018 Aug 16.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: MAP Kinase Signaling System*, Neuroblastoma/*genetics , Repressor Proteins/*genetics, Animals ; Cell Line, Tumor ; Cluster Analysis ; Disease Progression ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Genes, ras ; Genome, Human ; Genomics ; Homeodomain Proteins/metabolism ; Humans ; Mice ; Mice, Knockout ; Mice, Nude ; Mutation ; Neoplasm Recurrence, Local/genetics ; Neoplasm Transplantation ; Neuroblastoma/pathology ; Phenotype ; Phosphorylation ; Prognosis ; Repressor Proteins/metabolism ; Signal Transduction ; Transcription Factors/metabolism ; Treatment Outcome

المؤلفون: van Groningen T; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Koster J; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Valentijn LJ; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Zwijnenburg DA; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Akogul N; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Hasselt NE; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Broekmans M; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Haneveld F; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Nowakowska NE; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Bras J; Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands., van Noesel CJM; Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands., Jongejan A; Department of Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands., van Kampen AH; Department of Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands., Koster L; Department of Genome Diagnostics, Academic Medical Center, Amsterdam, the Netherlands., Baas F; Department of Genome Diagnostics, Academic Medical Center, Amsterdam, the Netherlands., van Dijk-Kerkhoven L; Department of Clinical Genetics, VU Medical Center, Amsterdam, the Netherlands., Huizer-Smit M; Department of Clinical Genetics, VU Medical Center, Amsterdam, the Netherlands., Lecca MC; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Chan A; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Lakeman A; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Molenaar P; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Volckmann R; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Westerhout EM; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Hamdi M; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., van Sluis PG; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Ebus ME; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Molenaar JJ; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Tytgat GA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands., Westerman BA; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., van Nes J; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands., Versteeg R; Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands.

المصدر: Nature genetics [Nat Genet] 2017 Aug; Vol. 49 (8), pp. 1261-1266. Date of Electronic Publication: 2017 Jun 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat Genet Subsets: MEDLINE

مواضيع طبية MeSH: Epigenesis, Genetic*, Cell Differentiation/*genetics , Neuroblastoma/*genetics , Neuroblastoma/*pathology, AC133 Antigen/genetics ; Adrenergic Neurons/cytology ; Cell Line, Tumor ; Cell Lineage ; Homeodomain Proteins/genetics ; Humans ; Mesoderm/cytology ; Transcription Factors/metabolism ; Transcriptome

المؤلفون: Bate-Eya LT; Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Gierman HJ; Department of Pediatric Oncology, Emma Kinderziekenhuis, Amsterdam, The Netherlands., Ebus ME; Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Koster J; Department of Oncogenomics Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Caron HN; Department of Pediatric Oncology, Emma Kinderziekenhuis, Amsterdam, The Netherlands., Versteeg R; Department of Oncogenomics Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Dolman MEM; Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Molenaar JJ; Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address: j.j.molenaar@prinsesmaximacentrum.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Apr; Vol. 75, pp. 63-72. Date of Electronic Publication: 2017 Feb 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Enhancer of Zeste Homolog 2 Protein/*physiology , Histone-Lysine N-Methyltransferase/*antagonists & inhibitors , Neuroblastoma/*enzymology, Benzamides/pharmacology ; Biphenyl Compounds ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Survival/physiology ; Chromosome Aberrations ; Chromosomes, Human, Pair 7 ; Down-Regulation/drug effects ; Enhancer of Zeste Homolog 2 Protein/metabolism ; Enzyme Inhibitors/pharmacology ; Gene Knockdown Techniques ; Gene Rearrangement ; Histone Methyltransferases ; Histone-Lysine N-Methyltransferase/physiology ; Humans ; Indoles/pharmacology ; Morpholines ; Neuroblastoma/physiopathology ; Prognosis ; Pyridones/pharmacology

المؤلفون: Dolman ME; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. memdolman@gmail.com., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, England., Ebus ME; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., den Hartog IJ; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., van Noesel CJ; Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England., Hallsworth A; Division of Clinical Studies, The Institute of Cancer Research, London, England., Robinson SP; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England., Petrie K; Division of Clinical Studies, The Institute of Cancer Research, London, England., Sparidans RW; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands., Kok RJ; Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, the Netherlands., Versteeg R; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Caron HN; Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, England., Molenaar JJ; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Nov 15; Vol. 21 (22), pp. 5100-9. Date of Electronic Publication: 2015 Jul 22.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Neuroblastoma/*drug therapy , Nuclear Proteins/*genetics , Oncogene Proteins/*genetics , Piperidines/*administration & dosage , Protein Kinase Inhibitors/*administration & dosage , Pyrazoles/*administration & dosage, Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cyclin-Dependent Kinase 2/biosynthesis ; Cyclin-Dependent Kinase 2/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; N-Myc Proto-Oncogene Protein ; Neuroblastoma/genetics ; Neuroblastoma/pathology ; Nuclear Proteins/biosynthesis ; Oncogene Proteins/biosynthesis ; Xenograft Model Antitumor Assays

المؤلفون: Eleveld TF; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Oldridge DA; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Bernard V; ICGEX Platform, Institut Curie, Paris, France., Koster J; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Colmet Daage L; 1] ICGEX Platform, Institut Curie, Paris, France. [2] Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France., Diskin SJ; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Schild L; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Bentahar NB; ICGEX Platform, Institut Curie, Paris, France., Bellini A; Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France., Chicard M; Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France., Lapouble E; Unité de Génétique Somatique, Institut Curie, Paris, France., Combaret V; Centre Léon-Bérard, Laboratoire de Recherche Translationnelle Lyon, Lyon, France., Legoix-Né P; ICGEX Platform, Institut Curie, Paris, France., Michon J; Département de Pédiatrie, Institut Curie, Paris, France., Pugh TJ; Princess Margaret Cancer Centre, University Health Network; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Hart LS; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Rader J; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Attiyeh EF; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Wei JS; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA., Zhang S; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA., Naranjo A; Department of Biostatistics, University of Florida, Children's Oncology Group (COG), Gainesville, Florida, USA., Gastier-Foster JM; 1] The Ohio State University College of Medicine, Columbus, Ohio, USA. [2] Biopathology Center, Nationwide Children's Hospital, Columbus, Ohio, USA., Hogarty MD; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Asgharzadeh S; 1] Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA. [2] Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA. [3] Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Smith MA; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Guidry Auvil JM; Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA., Watkins TB; Translational Cancer Therapeutics Laboratory, Cancer Research UK, London, UK., Zwijnenburg DA; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Ebus ME; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., van Sluis P; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Hakkert A; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., van Wezel E; 1] Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands. [2] Landsteiner Laboratory, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., van der Schoot CE; 1] Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands. [2] Landsteiner Laboratory, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Westerhout EM; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Schulte JH; 1] Department of Pediatric Oncology and Hematology, Charité University Medicine, Berlin, Germany. [2] German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany. [3] Department of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany. [4] Translational Neuro-Oncology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany., Tytgat GA; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Dolman ME; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Janoueix-Lerosey I; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France., Gerhard DS; Biopathology Center, Nationwide Children's Hospital, Columbus, Ohio, USA., Caron HN; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Delattre O; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France., Khan J; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA., Versteeg R; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Schleiermacher G; 1] Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France. [2] Département de Pédiatrie, Institut Curie, Paris, France. [3] INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France., Molenaar JJ; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands., Maris JM; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

المصدر: Nature genetics [Nat Genet] 2015 Aug; Vol. 47 (8), pp. 864-71. Date of Electronic Publication: 2015 Jun 29.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat Genet Subsets: MEDLINE

مواضيع طبية MeSH: Mutation*, MAP Kinase Signaling System/*genetics , Mitogen-Activated Protein Kinases/*genetics , Neoplasm Recurrence, Local/*genetics , Neuroblastoma/*genetics , ras Proteins/*genetics, Anaplastic Lymphoma Kinase ; Animals ; Benzimidazoles/pharmacology ; Blotting, Western ; Cell Line, Tumor ; Child ; Child, Preschool ; Chromosome Aberrations ; Cyclin-Dependent Kinase Inhibitor p16/genetics ; Cyclin-Dependent Kinase Inhibitor p16/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; HEK293 Cells ; Humans ; Infant ; Male ; Mice, SCID ; Mitogen-Activated Protein Kinases/metabolism ; Neuroblastoma/drug therapy ; Neuroblastoma/pathology ; Phosphorylation/drug effects ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor Protein-Tyrosine Kinases/metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Xenograft Model Antitumor Assays ; ras Proteins/metabolism

المؤلفون: Bate-Eya LT; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Ebus ME; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Koster J; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., den Hartog IJ; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Zwijnenburg DA; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Schild L; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., van der Ploeg I; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Dolman ME; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Caron HN; Department of Paediatric Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Versteeg R; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands., Molenaar JJ; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands. Electronic address: j.j.molenaar@amc.uva.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2014 Feb; Vol. 50 (3), pp. 628-37. Date of Electronic Publication: 2013 Dec 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cell Line, Tumor*, Neuroblastoma/*genetics , Neuroblastoma/*pathology, Animals ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Child ; Child, Preschool ; Culture Media, Serum-Free ; Genotype ; Humans ; Infant ; Mice ; Mice, Nude ; Neuroblastoma/metabolism ; Phenotype ; RNA, Messenger/genetics ; RNA, Messenger/metabolism